GSC-000829, a selective FGFR2/FGFR3 inhibitor, for cancer therapy

Nov. 20, 2024

Changchun Genescience Pharmaceuticals Co. Ltd. has reported GSC-000829, a novel and selective FGFR2/FGFR3 inhibitor being developed for the potential treatment of cancer.

BioWorld Science Conferences New compound AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Cancer

Today's news in brief

BioWorld

BioWorld briefs for April 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 10, 2025.

mRNA-based vaccine is immunogenic, protective in Lyme disease

BioWorld Science

Lyme disease is a multisystemic zoonotic infection caused by Borrelia burgdorferi bacteria transmitted by ticks. Lyme disease is a public health problem because...

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Alzheon’s lead candidate misses a phase III in early Alzheimer’s

BioWorld

Alzheon Inc.’s oral treatment for people in the early stages of Alzheimer’s disease missed its phase III primary endpoint, adding yet another therapy to a long...